Despite the patent dispute, Dong-A ST has released Dapapro, the first generic of SGLT-2 diabetes treatment Forxiga. Dapapro was listed for the upper limit of 684 won this month. According to industries on the 7th, Dong-A ST started selling with Dapapro salary registration. Dapapro is a prodrug product with a different chemical structure from the original. When Dapapro is absorbed, the structure changes afterwards, showing the same medicinal effect as Forxiga. SGLT-2 inhibitors such as Forxiga and Dapapro have the effect of lowering blood sugar by selectively and reversibly blocking SGLT-2 involved in glucose absorption, inducing the remaining glucose to be discharged into urine.

It succeeded in evadin